KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Healthcare

SK’s Drug Maker Unit to Become a Globally Leading Healthcare Firm

 790 total views,  1 views today

Hayoon Kim by Hayoon Kim
PUBLISHED: July 5, 2021 UPDATED: July 6, 2021
in Healthcare, SK, Tech Industry
0
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.

SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.

SK Group’s SK Biopharmaceuticals Co. shared that it plans to land a leading position among the world’s top healthcare companies. Moreover, the innovative next-gen drug developer aims to achieve the goal by 2030, with its enterprise value hitting 50 trillion won ($44 billion).

During SK’s company-wide “Financial Story” online event, SK Biopharmaceuticals announced its long-term plan to expand its business scope. Currently, the company develops epilepsy-focused medications.

Previously in May 2020, SK Biopharmaceuticals developed Cenobamate, a medicine treating partial epileptic seizure onsets. In the US, it distributed the drug under the brand name Xcopri. The company also released the drug to Germany in June this year.

Developing New Treatment for Neurological Conditions

For its newest objective, the SK unit would also manufacture medication for mental disorders, rare neurological conditions, and even cancer. SK Biopharmaceuticals CEO Cho Jeong-Woo stated that SK Biopharmaceuticals’ would introduce brand new products optimized for treating rare neurological diseases before 2025.

CEO Cho also said that the company is also researching medications for a broad range of mental disorders. To this end, SK Biopharmaceuticals strategically teamed up with pharmaceutical companies across various Asian and European markets.

Furthermore, CEO Cho revealed that the drug developer and researcher would increase its marketing efforts twofold. In particular, SK Biopharmaceuticals would strengthen operations globally and in the US. As a result, its corporate value could reach 25 trillion won ($23 billion) after five years.

During 2021’s first quarter, SK Biopharmaceuticals’ overall sales rose to 140 billion won from the previous 3.9 billion won, increasing over thirty-six times. Notably, this figure is a significant increase from the company’s record in the same period a year earlier.

Strengthening Company Capacity

SK Biopharmaceuticals also plans to introduce new drugs for central nervous system treatment across the US market. As part of this goal, the company would invest more in research and development. It would also increase funding for drug candidate scouting.

According to the drug maker, it plans to accelerate its digital transformation by utilizing artificial intelligence in drug development operations. SK Biopharmaceuticals would also employ RNA-based drug technologies to create treatments and medication.

Meanwhile, SK Biopharmaceuticals’ latest sustainable development report indicated that it has actively reinforced its ESG management drive. The drugmaker also plans to meet SK Group’s carbon neutrality vision.

Recently, SK Group announced that it would achieve carbon neutrality before the UN-passed 2050 target.

Check out other must-read articles from KoreaTechToday:

  • KT Develops Next-Gen Neuro-Electronic Therapy Tech with NeuroSigma
  • HCI Tech Startup Impressivo to Unite Fitness and Healthcare Solutions
  • AI Medical Tech Startup VUNO Enhances Samsung’s X-ray System
  • Samsung Promotes AI Healthcare Startups with Ada Health Investment
What’s your thoughts?
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
Tags: drugdrug developerhealthcaremedicineSK BiopharmacueticalsSK Group

Related Posts

South Korea to commercialize Quantum Cryptography Communications
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
Tech Industry

South Korea to commercialize Quantum Cryptography Communications

March 10, 2023
GC Biopharma to launch first-in-class rare disorder medications in the global market
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
Healthcare

GC Biopharma to launch first-in-class rare disorder medications in the global market

March 2, 2023
SK Telecom to expand the Korean AI Ecosystem
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
AI

SK Telecom to expand the Korean AI Ecosystem

March 1, 2023
South Korea plans Urban Air Mobility Air Taxi services by 2025
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
Tech Industry

South Korea plans Urban Air Mobility Air Taxi services by 2025

February 24, 2023
South Korean Govt shares strategic blueprint to become 5th biggest metaverse market globally
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
metaverse

South Korean Govt shares strategic blueprint to become 5th biggest metaverse market globally

January 24, 2022
SK Group forms ‘SK ICT Alliance’ for AI chip development
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
5G

SK Group forms ‘SK ICT Alliance’ for AI chip development

January 11, 2022
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • Robots to help Police Patrol in South Korea

    0 shares
    Share 0 Tweet 0
  • South Korea plans Urban Air Mobility Air Taxi services by 2025

    0 shares
    Share 0 Tweet 0
  • SK On to introduce South Korea’s first LFP Battery Prototype

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • Outsourcing by Samsung to China Feared by Phone Parts Suppliers

    0 shares
    Share 0 Tweet 0
  • Netmarble subsidiary Metaverse Entertainment’s K-Pop virtual girl band MAVE has a smashing online debut

    0 shares
    Share 0 Tweet 0
  • KT Continues to Accelerate Its ‘Digico’ Transformation

    0 shares
    Share 0 Tweet 0
  • Top Eight Promising EdTech Startup Companies in South Korea

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |